Clinical pharmacology of antihypertensive drugs in children.

[1]  O. Andersson,et al.  Propranolol given twice daily in hypertension. , 2009, Acta medica Scandinavica.

[2]  H. Bang,et al.  Treatment of severe hypertension with Catapres (St 155). A comparative study of the effect of catapres and methyldopa in a series of hypertensive outpatients (WHO stage 3). , 2009, Acta medica Scandinavica.

[3]  A. Sinaiko,et al.  Management of severe childhood hypertension with minoxidil: a controlled clinical study. , 1977, The Journal of pediatrics.

[4]  E. Lieberman,et al.  Report of the task force on blood pressure control in children. , 1977, Pediatrics.

[5]  R. Fine,et al.  Minoxidil therapy in children with severe hypertension. , 1977, The Journal of pediatrics.

[6]  A. Sinaiko,et al.  HYDROCHLOROTHIAZIDE (HCT) THERAPY IN HYPERTENSIVE (HT) AND RENAL INSUFFICIENT (RI) CHILDREN: ELIMINATION KINETICS AND METABOLIC EFFECTS , 1977, Pediatric Research.

[7]  A. Marshall,et al.  EVALUATION OF BETA BLOCKADE, BENDROFLUAZIDE, AND PRAZOSIN IN SEVERE HYPERTENSION , 1977, The Lancet.

[8]  M. Moser,et al.  Long-Term Effects of Furosemide and Hydrochlorothiazide in Patients With Essential Hypertension , 1977, Angiology.

[9]  M. Schambelan,et al.  Treatment of high-renin hypertension with propranolol in children after renal transplantation. , 1977, The Journal of pediatrics.

[10]  D. Rovner,et al.  Spironolactone and hydrochlorothiazide in normal‐renin and low‐renin essential hypertension , 1977, Clinical pharmacology and therapeutics.

[11]  J. Brisbane,et al.  Colitis and hepatitis caused by methyldopa. , 1976, JAMA.

[12]  D. Richards,et al.  Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol. , 1976, British journal of clinical pharmacology.

[13]  A. Pruitt,et al.  Diuretic effect of furosemide in acute glomerulonephritis. , 1976, The Journal of pediatrics.

[14]  Brittain Rt,et al.  A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug. , 1976, British journal of clinical pharmacology.

[15]  K. C. Kwan,et al.  Pharmacokinetics of methyldopa in man. , 1976, The Journal of pharmacology and experimental therapeutics.

[16]  D. Shand,et al.  Proposed mechanisms of propranolol's antihypertensive effect in essential hypertension. , 1976, The New England journal of medicine.

[17]  R. Doll,et al.  RAUWOLFIA DERIVATIVES AND BREAST CANCER IN HYPERTENSIVE WOMEN , 1976, The Lancet.

[18]  S. Gutman,et al.  Methyldopa Hepatitis. A report of six cases and review of the literature. , 1976, The American journal of medicine.

[19]  M. White,et al.  Diuretic-induced interstitial nephritis. Occurrence in a patient with membranous glomerulonephritis. , 1976, JAMA.

[20]  A. Rosén,et al.  Absorption, metabolism, and excretion of hydrochlorothiazide , 1976, Clinical pharmacology and therapeutics.

[21]  Pfeifer Hj,et al.  Clinical toxicity of reserpine in hospitalized patients: a report from the Boston Collaborative Drug Surveillance Program. , 1976 .

[22]  E. Speers,et al.  Experience with prazosin in the treatment of patients with severe hypertension. , 1976, The Medical journal of Australia.

[23]  D. Hutcheon.  BENEFIT—RISK FACTORS ASSOCIATED WITH SUPPLEMENTAL POTASSIUM THERAPY , 1976, Journal of clinical pharmacology.

[24]  P. Bolli,et al.  Prazosin in normal subjects: plasma levels, blood pressure and heart rate. , 1976, British journal of clinical pharmacology.

[25]  J. Wauters.  Unusual complication of high-dose frusemide. , 1975, British medical journal.

[26]  R. Verwilghen,et al.  DANGERS OF PETROL USED AS SOLVENT , 1975, The Lancet.

[27]  W. Pettinger.  Clonidine: a new antihypertensive drug. , 1975, Lancet.

[28]  A. Scriabine,et al.  Analysis of the hypotensive action of prazosin. , 1975, Postgraduate medicine.

[29]  K. O’malley,et al.  Duration of hydralazine action in hypertension , 1975, Clinical pharmacology and therapeutics.

[30]  E. Freis,et al.  Effect of Treatment on Longevity in Spontaneously Hypertensive Rats , 1975, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[31]  M. Pfisterer,et al.  Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. , 1975, The American journal of cardiology.

[32]  Shand Dg.  Drug therapy: Propranolol. , 1975, The New England journal of medicine.

[33]  K. Nguyen,et al.  Effect of dosage regimen on natriuretic response to furosemide , 1975, Clinical pharmacology and therapeutics.

[34]  J. Oates,et al.  A loading‐maintenance regimen for more rapid initiation of the effect of guanethidine , 1975 .

[35]  J. Irias.  Hydralazine-induced lupus erythematosus-like syndrome. , 1975, American journal of diseases of children.

[36]  C. Rosendorff,et al.  Clinical evaluation of prazosin as the sole agent for the treatment of hypertension: a double-blind cross-over study with methyldopa. , 1975, Current therapeutic research, clinical and experimental.

[37]  L. Goldberg,et al.  Hydralazine therapy in hypertensive patients with idiopathic systemic lupus erythematosus. , 1975, Arthritis and rheumatism.

[38]  Trefor Owen Morgan,et al.  SODIUM RESTRICTION AND THIAZIDE DIURETICS IN THE TREATMENT OF HYPERTENSION , 1975, The Medical journal of Australia.

[39]  S. Makker.  Minoxidil in refractory hypertension. , 1975, The Journal of pediatrics.

[40]  F. Nijkamp,et al.  Central inhibitory effect of alpha-methyldopa on blood pressure, heart rate and body temperature of renal hypertensive rats. , 1975, European journal of pharmacology.

[41]  C. Dollery,et al.  Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man. , 1975, The Journal of pharmacology and experimental therapeutics.

[42]  A. Branellec,et al.  LYMPHOKINES AND NEPHROTIC SYNDROME , 1975, The Lancet.

[43]  P. Jones,et al.  Frusemide-induced pancreatitis. , 1975, British medical journal.

[44]  R. Tarazi,et al.  β-Adrenergic Blockade in Diuretic-Treated Patients with Essential Hypertension , 1975 .

[45]  D. Lowenthal,et al.  Pharmacokinetics of oral propranolol in chronic renal disease , 1974, Clinical pharmacology and therapeutics.

[46]  N. Levin,et al.  Pharmacokinetics of furosemide in advanced renal failure , 1974, Clinical pharmacology and therapeutics.

[47]  D. Shand.  Individualization of propranolol therapy. , 1974, The Medical clinics of North America.

[48]  E. Freis,et al.  Partial reduction of blood pressure and prevention of complications in hypertension. , 1974, The New England journal of medicine.

[49]  W. Mroczek,et al.  Prazosin in hypertension: a double-blind evaluation with methyldopa and placebo. , 1974, Current therapeutic research, clinical and experimental.

[50]  A. Roach,et al.  CENTRAL ADRENORECEPTORS AND THE CONTROL OF ARTERIAL BLOOD PRESSURE , 1974, Clinical and experimental pharmacology & physiology.

[51]  W. Kannel.  Role of blood pressure in cardiovascular morbidity and mortality. , 1974, Progress in cardiovascular diseases.

[52]  A. Roach,et al.  CENTRAL α‐ AND β‐ADRENOCEPTORS MODIFYING ARTERIAL BLOOD PRESSURE AND HEART RATE IN CONSCIOUS CATS , 1974 .

[53]  A. Forrey,et al.  Pharmacokinetics of furosemide in normal subjects and functionally anephric patients , 1974, Clinical pharmacology and therapeutics.

[54]  W. Mroczek,et al.  Large dose furosemide therapy for hypertension. Long-term use in 22 patients. , 1974, The American journal of cardiology.

[55]  J. Douglas,et al.  Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide-triamterene combination. , 1974, JAMA.

[56]  E. C. Ralph,et al.  Pharmacokinetics of orally administered furosemide , 1974 .

[57]  R. Spark,et al.  Low-renin hypertension. Restoration of normotension and renin responsiveness. , 1974, Archives of internal medicine.

[58]  B. Altura.  Peripheral Vascular Actions of α-Methyl-DOPA and Its Mode of Action on Arterioles 1 , 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[59]  O. L. Kline,et al.  SALT INTAKE AND EATING PATTERNS OF INFANTS AND CHILDREN IN RELATION TO BLOOD PRESSURE , 1974, Pediatrics.

[60]  D. Drayer,et al.  Hydralazine elimination in man , 1973, Clinical pharmacology and therapeutics.

[61]  D. Greenblatt,et al.  Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. , 1973, American heart journal.

[62]  E. Lew.  High blood pressure, other risk factors and longevity: the insurance viewpoint. , 1973, The American journal of medicine.

[63]  J. Koch-weser.  Vasodilation for Vasospastic Hypertension , 1973 .

[64]  D. Shand,et al.  Disposition of propranolol VI. Independent variation in steady‐state circulating drug concentrations and half‐life as a result of plasma drug binding in man , 1973, Clinical pharmacology and therapeutics.

[65]  I. Rubin,et al.  Toxicity of ethacrynic acid and furosemide. , 1973, American heart journal.

[66]  L. Hansson,et al.  Effects of Clonidine Withdrawal: Possible Mechanisms and Suggestions for Management , 1973, British medical journal.

[67]  A. Roach,et al.  The mechanism of the antihypertensive action of -methyldopa in hypertensive rats. , 1973, European journal of pharmacology.

[68]  K. Engelman,et al.  Bioavailability of potassium from a slow‐release tablet , 1973, Clinical pharmacology and therapeutics.

[69]  P. A. Zwieten.  The central action of antihypertensive drugs, mediated via central α ‐receptors , 1973 .

[70]  J. Laragh,et al.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. , 1972, The New England journal of medicine.

[71]  W. Mroczek,et al.  Prolonged treatment with clonidine: comparative antihypertensive effects alone and with a diuretic agent. , 1972, The American journal of cardiology.

[72]  E. D. Jacobson,et al.  Altered Vascular Responsiveness: Initial Hypotensive Mechanism of Thiazide Diuretics , 1972, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[73]  J. Vickers,et al.  Propranolol in hypertension: a study of long-term therapy, 1964-1970. , 1972, American heart journal.

[74]  C. Chidsey,et al.  Pharmacokinetic studies of minoxidil , 1972, Clinical pharmacology and therapeutics.

[75]  R. Zacest,et al.  Relation of hydralazine plasma concentration to dosage and hypotensive action , 1972, Clinical pharmacology and therapeutics.

[76]  R. Tarazi,et al.  Dependence of arterial pressure on intravascular volume in treated hypertensive patients. , 1972, The New England journal of medicine.

[77]  J. Koch-weser,et al.  Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. , 1972, The New England journal of medicine.

[78]  C. Chidsey,et al.  Combined Therapy with Vasodilator Drugs and Beta‐Adrenergic Blockade in Hypertension: A Comparative Study of Minoxidil and Hydralazine , 1972, Circulation.

[79]  G. Sharp,et al.  Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus. , 1972, Annals of internal medicine.

[80]  S. Carmody,et al.  Immunologic findings in patients receiving methyldopa: a prospective study. , 1971, The Journal of laboratory and clinical medicine.

[81]  R. Lloyd‐Mostyn,et al.  Ototoxicity of intravenous frusemide. , 1971, Lancet.

[82]  J. Sheldon,et al.  A comparison of the effects of hydrochlorothiazide and of frusemide in the treatment of hypertensive patients. , 1971, The Quarterly journal of medicine.

[83]  T. Mckenna,et al.  Potassium-sparing Agents during Diuretic Therapy in Hypertension , 1971, British medical journal.

[84]  F. Finnerty,et al.  Furosemide in essential hypertension. A statistical analysis of three double-blind studies. , 1971, Archives of internal medicine.

[85]  C. Duarte,et al.  Thiazide-induced hypercalcemia. , 1971, The New England journal of medicine.

[86]  F. Finnerty.  Relationship of extracellular fluid volume to the development of drug resistance in the hypertensive patient. , 1971, American heart journal.

[87]  W. Kannel.  The origins and evils of essential hypertension. , 1971, The New England journal of medicine.

[88]  A. Leth.  Changes in Plasma and Extracellular Fluid Volumes in Patients with Essential Hypertension During Long‐Term Treatment with Hydrochlorothiazide , 1970, Circulation.

[89]  R. Ogilvie,et al.  Effects of large and small doses of hydrochlorothiazide in hypertensive patients , 1970, Clinical pharmacology and therapeutics.

[90]  W. Mroczek,et al.  II. HEMODYNAMIC ASPECTS OF HYPERTENSION: Influence of Extracellular Fluid Volume on Response to Antihypertensive Drugs , 1970, Circulation research.

[91]  H. Perry,et al.  Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. , 1970, The Journal of laboratory and clinical medicine.

[92]  E. Frohlich,et al.  Long‐Term Thiazide Therapy in Essential Hypertension: Evidence for Persistent Alteration in Plasma Volume and Renin Activity , 1970, Circulation.

[93]  S. Ingbar,et al.  Interference in the measurement of plasma 11-hydroxycorticosteroids caused by spironolactone administration. , 1970, The New England journal of medicine.

[94]  W. Mroczek,et al.  The Value of Aggressive Therapy in the Hypertensive Patient with Azotemia , 1969, Circulation.

[95]  J. Loggie.  Hypertension in children and adolescents. I. Causes and diagnostic studies. , 1969, The Journal of pediatrics.

[96]  A. Gutman,et al.  Uric acid nephrolithiasis. , 1968, The American journal of medicine.

[97]  I. Hanenson,et al.  The effects of alpha-methyldopa on renal function in hypertensive patients. , 1968, American heart journal.

[98]  T. Gaffney,et al.  Effect of methyldopa, reserpine and guanethidine on hindleg vascular resistance. , 1968, The Journal of pharmacology and experimental therapeutics.

[99]  K. Drummond,et al.  Hypertension and seizures following methyldopa infusion. , 1967, Pediatrics.

[100]  J. Laragh,et al.  Hyperuricemia in primary and renal hypertension. , 1966, The New England journal of medicine.

[101]  B. Kjessler.  NURSING NEEDS IN THE GERIATRIC WARD. , 1964, Lancet.

[102]  P. Cannon,et al.  THE METABOLISM OF METHYLDOPA IN HYPERTENSIVE HUMAN SUBJECTS. , 1964, The Journal of pharmacology and experimental therapeutics.

[103]  L. Lasagna,et al.  The effect of dosage regimen on the diuretic efficacy of chlorothiazide in human subjects. , 1961, The Journal of pharmacology and experimental therapeutics.

[104]  A. P. Shapiro,et al.  Effect of Thiazides on Carbohydrate Metabolism in Patients with Hypertension , 1961 .

[105]  B. Winer.  The Antihypertensive Actions of Benzothiadiazines , 1961, Circulation.

[106]  J. Conway,et al.  Hemodynamic and Hypotensive Effects of Long‐term Therapy with Chlorothiazide , 1960, Circulation.

[107]  E. Freis,et al.  Relationship Between Plasma and Extracellular Fluid Volume Depletion and the Antihypertensive Effect of Chlorothiazide , 1959, Circulation.

[108]  D. A. Duncan,et al.  Reserpine-induced gastrointestinal hemorrhage. , 1959, Journal of the American Medical Association.

[109]  R. W. Achor,et al.  Depressive Reactions in Hypertensive Patients: A Comparison of Those Treated with Rauwolfia and Those Receiving No Specific Antihypertensive Treatment , 1959, Circulation.

[110]  M. Clark,et al.  Gastric secretion as influenced by Rauwolfia alkaloids. , 1957, Annals of internal medicine.

[111]  H. Hecht,et al.  Cardiovascular and renal adjustments to a hypotensive agent (l'hydrazinophthalazine: Ciba BA-5968: apresoline). , 1952, The Journal of clinical investigation.

[112]  H. Eder,et al.  Dietary treatment of hypertension; clinical and metabolic studies of patients on the rice-fruit diet. , 1950, The Journal of clinical investigation.

[113]  W. Kempner.  Treatment of hypertensive vascular disease with rice diet. , 1948, Archives of internal medicine.

[114]  J. Webster,et al.  Adverse reactions to beta-blocking drugs: a review. , 1976, Postgraduate medical journal.

[115]  E. Frohlich.  Use and abuse of diuretics , 1975 .

[116]  D. Greenblatt,et al.  Gynecomastia and impotence: complications of spironolactone therapy. , 1973, JAMA.

[117]  J. Miller,et al.  Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children. , 1973, The Journal of pediatrics.

[118]  H. Perry.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. , 1973, The American journal of medicine.

[119]  H. Ibsen,et al.  The effect of triamterene on plasma and extracellular fluid volume and blood pressure in ten thiazide-treated hypokalemic patients with essential hypertension. , 1972, Scandinavian journal of clinical and laboratory investigation.

[120]  R. Tarazi,et al.  Similar effects of hydrochlorothiazide and spironolactone on plasma renin activity in essential hypertension. , 1972, Cleveland Clinic quarterly.

[121]  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. , 1967, JAMA.

[122]  J. Moyer,et al.  Some observations on the pharmacology of hydrochlorothiazide. , 1959, The American journal of cardiology.